Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7763206 | 0.87 | MME (0.41) | MMEACECPA1ACE2ANPEP | |
| SCHEMBL7761454 | 0.82 | ANPEP (0.45) | MMP2MMP3ANPEPLTA4H | |
| SCHEMBL7763157 | 0.80 | MMP2 (0.49) | MMP2MMP3 | |
| SCHEMBL7765144 | 0.77 | MME (0.37) | MMP2MMP3MMEACECPA1 | |
| SCHEMBL7765135 | 0.77 | MME (0.37) | MMP2MMP3MMEACECPA1 | |
| SCHEMBL7765130 | 0.77 | MME (0.37) | MMP2MMP3MMEACECPA1 | |
| SCHEMBL6270672 | 0.68 | MMP2 (0.65) | MMP2MMP3 | |
| SCHEMBL6270662 | 0.68 | MMP2 (0.65) | MMP2MMP3 | |
| SCHEMBL15304889 | 0.67 | MEN1 (0.54) | — | |
| SCHEMBL11126931 | 0.67 | MME (0.60) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |